BridgeMD
New treatment option for Atrial Fibrillation
Official title Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
ClinicalTrials.gov ID: NCT06401616
What this study is testing
What is OAC will be discontinued for the duration of the trial?
OAC will be discontinued for the duration of the trial is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for atrial fibrillation.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \> 18 years
- Previously undergone any type of cardiac surgical procedure including any type of surgical LAA closure (use of any of the following techniques...
- Documented history of paroxysmal, persistent, or permanent atrial fibrillation or atrial flutter according to the electronic patient record
- Informed consent
You likely can't join if
- Not receiving OAC (warfarin/DOAC)
- Patient specific conditions requiring OAC (e.g.mechanical valve, previous pulmonary embolism)
- Renal impairment (estimated glomerular filtration rate \< 30)
- Allergy to contrast media
- Pregnancy or breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Copenhagen, Capital Region, Denmark
- Gentofte Municipality, Capital Region, Denmark
- Herning, Central Jutland, Denmark
- Aalborg, North Denmark, Denmark
- Aarhus, Region Midt, Denmark
- Odense, Region Syddanmark, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Copenhagen, Capital Region, Denmark; Gentofte Municipality, Capital Region, Denmark; Herning, Central Jutland, Denmark; Aalborg, North Denmark, Denmark; Aarhus, Region Midt, Denmark; Odense, Region Syddanmark, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.